Literature DB >> 2113614

Direct evidence for the contribution of the unique I-ANOD to the development of insulitis in non-obese diabetic mice.

T Miyazaki1, M Uno, M Uehira, H Kikutani, T Kishimoto, M Kimoto, H Nishimoto, J Miyazaki, K Yamamura.   

Abstract

Insulin-dependent diabetes mellitus is characterized by the infiltration of lymphocytes into the islets of Langerhans of the pancreas (insulitis) followed by destruction of insulin-secreting beta-cells leading to overt diabetes. The best model for the disease is the non-obese diabetic (NOD) mouse. Two unusual features of the class II major histocompatibility complex (MHC) of the NOD mouse are the absence of I-E and the presence of unique I-A molecules (I-ANOD), in which aspartic acid at position 57 of the beta-chain is replaced by serine. This feature is also found in the HLA-DQ chain of many Caucasians with insulin-dependent diabetes mellitus. We have previously reported that the expression of I-E prevents the development of insulitis in NOD mouse. Here we report that the expression of I-Ak (A alpha kA beta k) in transgenic NOD mice can also prevent insulitis, and that this protection is seen not only when the I-A beta-chain has aspartic acid as residue 57, but also when this residue is serine. These results show that the single amino-acid substitution at position 57 of the I-A beta-chain from aspartic acid to serine is not sufficient for the development of the disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2113614     DOI: 10.1038/345722a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  47 in total

1.  Specificity of peptide selection by antigen-presenting cells homozygous or heterozygous for expression of class II MHC molecules: The lack of competition.

Authors:  Anish Suri; James J Walters; Osami Kanagawa; Michael L Gross; Emil R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

Review 2.  Genetic susceptibility in type 1 diabetes and its associated autoimmune disorders.

Authors:  Akane Ide; George S Eisenbarth
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 3.  The differentiation of the immune system towards anti-islet autoimmunity. Clinical prospects.

Authors:  C Boitard
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

Review 4.  Non-obese diabetic transgenic mouse.

Authors:  K Yamamura; T Miyazaki; M Uno; T Toyonaga; J Miyazaki
Journal:  Springer Semin Immunopathol       Date:  1992

Review 5.  Genetics of type 1 diabetes.

Authors:  Janelle A Noble; Henry A Erlich
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 6.  Transgenic regulation in laboratory animals.

Authors:  S Rusconi
Journal:  Experientia       Date:  1991-09-15

7.  Fibroblast growth factor receptor 5 (FGFR5) is a co-receptor for FGFR1 that is up-regulated in beta-cells by cytokine-induced inflammation.

Authors:  Romario Regeenes; Pamuditha N Silva; Huntley H Chang; Edith J Arany; Andrey I Shukalyuk; Julie Audet; Dawn M Kilkenny; Jonathan V Rocheleau
Journal:  J Biol Chem       Date:  2018-09-14       Impact factor: 5.157

8.  Induction of insulitis by glutamic acid decarboxylase peptide-specific and HLA-DQ8-restricted CD4(+) T cells from human DQ transgenic mice.

Authors:  L Wen; F S Wong; L Burkly; M Altieri; C Mamalaki; D Kioussis; R A Flavell; R S Sherwin
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

9.  L cells expressing DQ molecules of the DR3 and DR4 haplotypes: reactivity patterns with mAbs.

Authors:  D S Monos; E Czanky; S J Ono; S F Radka; D Kappes; J L Strominger
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

10.  RFLP analysis of the MHC class III region defines unique haplotypes for the non-obese diabetic, cataract Shionogi and the non-obese non-diabetic mouse strains.

Authors:  T Lund; S Shaikh; E Kendall; R D Campbell; M Hattori; S Makino; A Cooke
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.